bit.ly
Rewriting the Rulebook of Blood
At ASH 2025, Eric Pietras, PhD, highlights how aging, inflammation, and metabolism drive clonal hematopoiesis—and shape cancer and cardiovascular risk.
Real-time updates, highlights, and insights from the 66th ASH Annual Meeting and Exposition, the premier global event in #hematology. Get ready to geek out on the science and network with the brightest minds in #heme and #hemeonc! #ASH24|#ASHKudos|#ASHRunWalk|#ASHaiku|#ASHThrowback
Feed on BlueskyFeeds Stats
- 💙 Liked by 50 users
- 📅 Updated 2 months ago
- ⚙️ Provider skyfeed.me
ASH Annual Meeting Likes over time
Like count prediction
The feed ASH Annual Meeting gains approximately 2 likes per month.
Feed Preview for ASH Annual Meeting
#ASH25: Did you know that clonal hematopoiesis affects at least 20% of adults over 60? Cancer Center's @ericpietras.bsky.social, PhD, shares his insights on the role of this condition in cancer and aging at the 2025 American Society of Hematology Presidential Symposium ⬇️
bit.ly/3KOKdoi
0
0
1
MRD is “a credible intermediate endpoint” for some patients with newly diagnosed #AML. Presented at #ASH25 by @jessetettero.bsky.social of @fralinbiomed.bsky.social.
bit.ly/4j2f79h
#leusm
0
0
0
Don’t forget to claim your CME/MOC credit for attending #ASH25! ✅ Complete the evaluation survey by April 10, 2026, to claim credit and print your certificate. Claim now: ow.ly/HGGO50XKxJy
#HemeSky #MedSky #Hematology #HemeOnc
0
0
1
The Lymphoma Hub was pleased to speak with Alexey Danilov at #ASH25.
We asked, What are the latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL?
Watch here: loom.ly/M45g2y4
#lymsm #leusm #MedEd
0
0
0
Dr. Oyedeji’s #NIH-funded SCD study was cut midway. Such funding cuts not only disrupt patient care but also may discourage researchers, particularly those from underrepresented backgrounds.
Learn more: ow.ly/aYaV50XKqQU
#Fight4Hematology #ResearchSavesLives #SickleCell #HemeSky
0
1
4
@jyves94.bsky.social
about 15 hours ago✨ #ASH2025 : au lieu d’une production en laboratoire, les #CAR_T 🧬 sont créés dans le corps, grâce à une technologies in vivo
Cela pourrait rendre les thérapies pour le #MyélomeMultiple 🩸 + rapides, + faciles & accessibles à un + grand nombre de patients
www.gelbe-liste.de/onkologie/in...
www.gelbe-liste.de
ASH 2025: CAR-T-Zell-Therapie ohne Lymphodepletion und lange Produktionszeit | Gelbe Liste
Mit einer Gentherapie im Körper des Patienten lässt sich womöglich eine effektive CAR-T-Zell-Therapie durchführen – zum Beispiel beim multiplen Myelom.
0
0
1
We're leaving #ASH25 filled with even more inspiration and determination to bring innovative treatment options to patients living with challenging blood cancers.
Watch to see how our team engaged at this year’s meeting! 🎥 🩸
0
0
0
What’s New in Myeloma Research? Join our speakers online on Wednesday, January 7, 2026, to hear about the top myeloma research presented at ASH— all from a patient perspective. Register before spots are gone: mmsm.link/4pOxSz1
#IMFASH25 #ASH25 #mmsm
0
0
0
🎥 During #ASH2025 Annual Meeting, Hervé Affagard, CEO and co-founder of MaaT Pharma, was interviewed by Brad Loncar for BiotechTV.
🙏 Many thanks for this insightful discussion and for spotlighting our work.
👉 Watch the full interview: www.biotechtv.com/post/ma….
@biotechtv.bsky.social
www.biotechtv.com
ASH 2025: MaaT Pharma's microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval - the pivotal data was presented in an oral at ASH this week
Founder and CEO Hervé Affagard walks us through how this treatment works and highlights the ASH presentation and one year survival data the company has accrued. Plus, how compassionate use is going in...
0
0
1
Also no difference in hours spent at infusion center between IV vs SQ formulations.
Overall, these data are first & largest of patient-reported time burden with different bispecifics in FL & DLBCL, and provide concrete data to better counsel patients as part of shared decision-making. #ASH25 #lymsm
0
0
0
At #ASH25, we presented our patient-reported time toxicity study in 120 pts w/ R/R FL & DLBCL on mosun, glofi & epcor. Mosun & glofi w/⬇️all-cause healthcare visits & hours spent on cancer-related care in past 30 days v epcor.
More details in this #thread. #lymsm
www.sciencedirect.com/sci….
1
0
1
MorningSun trial shows SC mosunetuzumab is effective & well-tolerated for elderly or CIT-ineligible #DLBCL patients. Featuring SCRI’s Dr. Jeff Sharman:
www.hmpgloballearningnetw…. #ASH25 #InnovationInOncology #SCRI
www.hmpgloballearningnetwork.com
Client Challenge
Please enable JavaScript to proceed.
0
0
0
Anito-Cel Yields Durable Responses With Manageable Safety in R/R Multiple Myeloma @mdanderson.bsky.social @ash.hematology.org #ASH25 #mmsm #oncology www.onclive.com/view/anit….
www.onclive.com
Anito-Cel Yields Durable Responses With Manageable Safety in R/R Multiple Myeloma | OncLive
Anito-cel showed deepening responses in patients with relapsed or refractory myeloma enrolled in the phase 2 iMMagine-1 study.
0
0
0
@rahulbanerjeemd.bsky.social of @fredhutch.org discusses major advances in bispecific antibodies presented at #ASH25 for #multipleMyeloma.
Read and watch more here: ➡️ bit.ly/3KMNsg0
#myeloma #mmsm
0
1
1
"Now that you see it allowing half-matched siblings and now in these genetically mismatched, unrelated donors, it's really cool." -- Wendy Stock, MD, commenting on post-transplant cyclophosphamide expanding the donor pool for #stemcell transplants. #ash25
www.medpagetoday.com/meet….
www.medpagetoday.com
Potential Game-Changing Impact on Mismatched Unrelated Blood Cell Transplantation
Similar survival, GVHD rates with 7/8 or
1
0
0
"It was a knockout ... We couldn't find a weak point." -- Wojciech Jurczak, MD, PhD, on the reported efficacy of pirtobrutinib (Jaypirca) for newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma. #ash25 @ash.hematology.org
www.medpagetoday.com/meet….
www.medpagetoday.com
New BTK Inhibitor Makes Case for Earlier Use in CLL
PFS improvement of 80% and early OS difference with pirtobrutinib versus older regimen
1
0
0
@jyves94.bsky.social
1 day agoCongrès #ASH2025 : des études présentées à la 67e édition du congrès de l’American Society of Hematology #ASH25 soulignent le rôle croissant des nouvelles thérapies & #ImmunoThérapies efficaces sans #Chimiothérapie dans le traitement des #CancersDuSang 🩸
www.lequotidiendumedecin.….
www.lequotidiendumedecin.fr
Congrès ASH : des approches sans chimiothérapie efficaces dans les cancers du sang
Au congrès 2025 de l’American Society of Hematology (6 au 9 décembre 2025), des études présentées ont illustré l’importance croissante des nouvelles thérapies et immunothérapies dans le traitement des...
0
0
1
Final data from the ECWM-1 showed that adding bortezomib to DRC does not convey a survival benefit for patients with #WaldenströmMacroglobulinemia. Presented at #ASH25, covered by @cancertherapyadv.bsky.social.
bit.ly/3MuKGMU
0
0
0
Expert faculty are bringing standout #ASH25 research to a city near you! Highlights of ASH in North America is happening soon.
Get curated insights in an intimate learning environment. Rates increase after Jan. 2! Register: ow.ly/JBsC50XsZwR #Hemesky #Medsky
0
0
0
Bezuclastinib Shows Promise in Nonadvanced Systemic Mastocytosis
@ash.hematology.org #ASH25 #oncology
www.onclive.com/view/bezu….
www.onclive.com
Bezuclastinib Shows Promise in Nonadvanced Systemic Mastocytosis | OncLive
Bezuclastinib markedly improved symptoms and disease markers in nonadvanced systemic mastocytosis, showing durable benefit and a manageable safety profile.
0
0
0
Revumenib Shows Activity Across R/R KMT2A-Rearranged Acute Leukemia Subtypes
@ash.hematology.org @cityofhope.bsky.social #leusm #ASH25
www.onclive.com/view/revu….
www.onclive.com
Revumenib Shows Activity Across R/R KMT2A-Rearranged Acute Leukemia Subtypes | OncLive
Revumenib displayed responses irrespective of disease subtype in relapsed/refractory acute leukemia harboring a KMT2A rearrangement.
0
0
0
📰 Read all about the results of Jesse Tettero’s research on the HARMONY Platform—just presented at #ASH25 —in this excellent article from @ascopost.bsky.social 👇
ascopost.com/news/decembe...
#hematology #Leukemia #AML #RealWorldData #DataSharing #RWE
ascopost.com
New Pooled Analysis Strengthens Case for MRD as Surrogate Endpoint in AML
Measurable residual disease, regardless of method of assessment, is a robust individual-level predictor for overall survival among patients with acute myeloid leukemia who have already received induct...
0
0
1